
Zydus Lifesciences and MSN Laboratories have launched the first generic version of Bayer's Adempas (riociguat tablets) in the US across all five strengths after receiving USFDA approval, the companies announced on 5 October. The tablets are available in 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg strengths. MSN developed and manufactures the drug, while Zydus handles the US commercial launch.

Riociguat is indicated for adults with chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension, two rare and life-threatening lung conditions. Patients typically remain on treatment for life. According to Bayer's 2025 annual report, global sales of Adempas were approximately €745 million (around $850 million) in 2025. Sharvil Patel, managing director of Zydus, called the launch a milestone for the company's US business.
All six sources report the same factual launch: Zydus and MSN introduced the first US generic of Bayer's Adempas across five strengths after USFDA approval. The Hindu and CNBC-TV18 add that until now riociguat was available only as the branded product. Economic Times provides additional market context, noting Adempas lost US patent protection in 2026 and that Sandoz debuted a generic in Canada in 2024 and is awaiting FDA approval to launch in the US. Every outlet quotes Sharvil Patel and MSN Reddy identically on the milestone and technical challenge. No source carries a critical or government-angle frame, the coverage is uniformly neutral straight reporting. The next concrete item to watch is Sandoz's FDA approval status, which could affect market share.
Coverage: 6 sources, 6 neutral
Sources (6): cnbctv18.com (neutral report), abplive.com (neutral report), thehindubusinessline.com (neutral report), thehindu.com (neutral report), medicaldialogues.in (neutral report), economictimes.indiatimes.com (neutral report)
This brief was synthesised by AI from the 6 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 7 October 2026: this story now draws on 6 sources.